Lantern Pharma Inc. (LTRN) Form 8-K — May 15, 2026
Lantern Pharma reported Q1 2026 results showing a 27% year-over-year reduction in net loss to $3.3 million, driven by a 47% cut in R&D spending to $1.7 million. The company highlighted operational discipline and capital efficiency, advancing clinical programs like LP-300 and LP-184 while launching its withZeta.ai platform. The company closed a $4.4 million registered direct offering on May 14, 2026, issuing 1.45 million shares and warrants. Combined with $6.3 million in existing cash, pro forma liquidity is approximately $10.7 million, which management states will fund operations into the middle of the first quarter of 2027.
Key figures
- Revenue
- 0
- Debt Amount
- 4400000
- Cash Position
- 6300000
- Shares Outstanding
- 11304697
- Runway End
- mid-Q1 2027
- Ga Expense Q1
- 1700000
- Rd Expense Q1
- 1700000
- Offering Shares
- 1454175
- Pre Funded Warrants
- 681748
- Rd Reduction Percent
- 47
- Rd Expense Q1 Prior Year
- 3300000
- Unregistered Warrants
- 2135923
- Warrant Exercise Price
- 2.27
- Net Loss Reduction Percent
- 27
Price after filing
Close on the filing date to close N calendar days later (from $3.13). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.